Literature DB >> 10439449

Association of the enkephalinase gene with low amplitude P300 waves.

D E Comings1, G Dietz, J P Johnson, J P MacMurray.   

Abstract

Low amplitude of the P300 evoked potential waves has been linked to substance abuse. Defects in opioidergic genes regulating reward pathways have been implicated as risk factors in substance abuse. Since the rate of degradation of enkephalins regulates their CNS level, we focused on the MME gene for metallo-membrane endopeptidase (neutral endopeptidase, enkephalinase). We identified a GT repeat polymorphism 5' to the gene and examined its potential association with P300 wave amplitude in 25 male subjects with substance abuse. There was significant association of low mol. wt alleles with low amplitude of the P300 wave at the parietal (p = 0.0087) and coronal (p = 0.009) leads. These results support a role of endogenous opioids in the regulation of P300 wave amplitude.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10439449     DOI: 10.1097/00001756-199908020-00011

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  8 in total

1.  Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior.

Authors:  Kenneth Blum; Marlene Oscar-Berman; Rajendra D Badgaiyan; Tomas Palomo; Mark S Gold
Journal:  Med Hypotheses       Date:  2014-02-26       Impact factor: 1.538

2.  Developmental Endophenotypes: Indexing Genetic Risk for Substance Abuse with the P300 Brain Event-Related Potential.

Authors:  William G Iacono; Stephen M Malone
Journal:  Child Dev Perspect       Date:  2011-12-01

Review 3.  Alcohol: effects on neurobehavioral functions and the brain.

Authors:  Marlene Oscar-Berman; Ksenija Marinković
Journal:  Neuropsychol Rev       Date:  2007-09       Impact factor: 7.444

Review 4.  Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).

Authors:  Kenneth Blum; Thomas J H Chen; B William Downs; Abdalla Bowirrat; Roger L Waite; Eric R Braverman; Margaret Madigan; Marlene Oscar-Berman; Nicholas DiNubile; Eric Stice; John Giordano; Siobhan Morse; Mark Gold
Journal:  Postgrad Med       Date:  2009-11       Impact factor: 3.840

5.  Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates.

Authors:  Eric R Braverman; Thomas J H Chen; Thomas J Prihoda; William Sonntag; Brian Meshkin; B William Downs; Julie F Mengucci; Seth H Blum; Alison Notaro; Vanessa Arcuri; Michael Varshavskiy; Kenneth Blum
Journal:  Age (Dordr)       Date:  2007-05-12

6.  Association of neprilysin polymorphism with cerebral amyloid angiopathy.

Authors:  M Yamada; N Sodeyama; Y Itoh; A Takahashi; E Otomo; M Matsushita; H Mizusawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

7.  A neprilysin polymorphism and amyloid-beta plaques after traumatic brain injury.

Authors:  Victoria E Johnson; William Stewart; David I Graham; Janice E Stewart; Amy H Praestgaard; Douglas H Smith
Journal:  J Neurotrauma       Date:  2009-08       Impact factor: 5.269

Review 8.  An eight component decision-making model for problem gambling: a systems approach to stimulate integrative research.

Authors:  David Nussbaum; Kimia Honarmand; Richard Govoni; Martina Kalahani-Bargis; Stephanie Bass; Xinqun Ni; Kaitlyn Laforge; Andrea Burden; Kristoffer Romero; Sonya Basarke; Christine Courbasson; Wade Deamond
Journal:  J Gambl Stud       Date:  2011-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.